- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07464925
En fase 1-studie for sikkerhet og doseringsfastsettelse av GLIX1 hos voksne med tilbakevendende eller progressiv høygradig gliom
En åpen fase 1-studie for sikkerhet og doseringsfastsettelse av peroralt administrert GLIX1 hos voksne med tilbakevendende eller progressiv høygradig gliom
This is an open-label, multicenter dose-escalation study to be followed by a dose expansion to define the optimal dose of GLIX1 as monotherapy by reviewing safety and tolerability, disease characteristics and pharmacokinetic profiles and preliminary clinical activity in participants with a high grade diffuse glioma that progressed during or recurred after prior standard of care therapies or investigational therapies as clinically indicated.
Patients will be treated daily with GLIX1 capsules until disease progression or unacceptable safety.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Glioblastomas (GBMs) are the most common and aggressive primary malignant tumors in adult central nervous system. High-grade glioma almost always recur and/or progress, and upon progression treatment options are very limited with no universal standard therapy established.
GLIX1 is a small molecule administered PO (per os, i.e., orally), that targets the deoxyribonucleic acid (DNA) damage repair mechanism by enhancing Tet methylcytosine dioxygenase 2 (TET2) activity. Increasing the activity of the TET2 enzyme increases DNA oxidation at 5-methylcytosine residues. Such oxidation is normally processed by base excision repair. During base excision repair, a single stranded DNA break is formed. These single strand DNA breaks are well tolerated in normal cells. In cancer, alterations in DNA methylation are common and TET2 activity is inhibited, giving rise to increased DNA methylation in close genomic proximity. When GLIX1 agonizes TET2 activity in cancer cells, excessive base excision repair results in numerous single strand DNA breaks in close proximity, which ultimately converge to form double strand DNA breaks that overwhelm the repair capacity of these cancer cells, resulting in apoptotic cell death.
High-grade glioma have some of the lowest levels of genomic 5-hydroxymethylcytosine. Thus, enhancing the activity of the TET2 enzyme in these cells is likely to have the greatest effect in terms of treating cancers.
Indeed, GLIX1 has been shown to cross the blood brain barrier in rodents and has shown significant activity in various in vitro and in vivo GBM and glioma tumor models.
Studietype
Registrering (Antatt)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
California
-
Palo Alto, California, Forente stater, 94304
- Rekruttering
- Stanford University
-
Ta kontakt med:
- Lewis Naya
- Telefonnummer: (650) 725-0379
- E-post: secure-sci-cto-neuro-crcs@lists.stanford.edu
-
-
Florida
-
Tampa, Florida, Forente stater, 33612
- Rekruttering
- Moffitt Cancer Center
-
Hovedetterforsker:
- Patrick Grogan, MD
-
Ta kontakt med:
- Patrick Grogan, MD
- Telefonnummer: 813-745-8000
- E-post: Patrick.grogan@moffitt.org
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60611
- Rekruttering
- Northwestern Medicine
-
Ta kontakt med:
- Ditte Primdahl, MD
- Telefonnummer: 312-695-1202
- E-post: cancer@northwestern.edu
-
-
New York
-
New York, New York, Forente stater, 10016
- Rekruttering
- NYU Langone Health
-
Hovedetterforsker:
- Alexandra Miller, MD, PhD
-
Ta kontakt med:
- Alexandra Miller, MD
- Telefonnummer: (212) 731-6267
- E-post: cancertrials@nyulangone.org
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Main Inclusion Criteria:
-
Adult patients aged ≥18 years at the time of informed consent
-
Participants must have histologically confirmed Grade 3 or Grade 4 glioma
-
Recurrent or progressive disease
-
A maximum of two prior treatment lines
-
Interval of at least 3 months since the last day off of radiotherapy, unless tumor progression and index lesion is outside the prior radiation field.
-
Interval since last dose of systemic therapy and Baseline MRI of ≥28 days, except:
- for nitrosoureas (e.g., lomustine, carmustine, fotemustine): 42 days (6 weeks)
- for monoclonal antibodies: 42 days (6 weeks)
- for small molecules, 4 weeks or at least 5 half-lives (whatever is longer)
-
Recovered from all toxicities from prior treatments to Grade 1 or less by NCI CTCAE v6.0:
-
Participants receiving corticosteroids must be on a stable or decreasing dose of ≤6 mg daily dexamethasone (or ≤40 mg prednisone) for the 7 days prior to the start of study treatment.
-
Participants with seizures must be adequately controlled on a stable regimen of anti-epileptic drugs.
-
Adequate performance status: Eastern Cooperative Oncology Group (ECOG) 0 or 1.
-
Ability to swallow tablets or capsules.
-
Adequate hematological, liver and renal function.
-
Women of childbearing potential must have a negative serum pregnancy test result within 7 days prior to first dosing. Women must use a highly effective form of contraception (with Pearl Index <1%) for the duration of the study and for at least 3 months after the last dose of study medication.
-
Men with partners of childbearing potential must be willing to use condoms in combination with a second effective method of contraception by the partner during the study and for at least 3 months after the last dose of study medication.
Main Exclusion Criteria:
- Known contraindication for gadolinium (Gd) based, contrast-enhanced MRI
- Prior history of another invasive malignancy unless a complete remission was achieved at least 3 years prior to enrolment AND no additional therapy is required during the study period, except for anti-estrogen or androgen therapy and/or bisphosphonates or denosumab.
- Participants with known active or uncontrolled infection, and/or unexplained fever >38°C in the 3 days prior to the start of study treatment.
- Major non-tumor related surgical procedure or significant traumatic injury within 28 days prior to signing of consent.
- Receiving any investigational products (defined as treatment for which there is currently no regulatory authority-approved indication) within 4 weeks or 5 half-lives (whichever is the longest) prior to Baseline MRI.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: GLIX1
Escalating doses of GLIX1, starting at a dose of 1000 mg/day |
Administered orally, once daily, in cycles of 28 days |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Safety Profile of GLIX1 (%Participants with Treatment-emergent Adverse Events)
Tidsramme: From first administration of GLIX1 (Cycle 1 Day 1) until 30 days following last dose administration
|
%Participants with treatment-emergent adverse events (TEAEs) based on CTCAE v6.0 |
From first administration of GLIX1 (Cycle 1 Day 1) until 30 days following last dose administration
|
|
Maximal Tolerated Dose and/or Recommended Dose
Tidsramme: From first administration of GLIX1 (Cycle 1 Day 1) until one cycle of 28 days is complete
|
Maximal Tolerated Dose (MTD) is selected as the dose for which the isotonic estimate of the Dose Limiting Toxicity (DLT) rate is closest to the target rate of 0.3 |
From first administration of GLIX1 (Cycle 1 Day 1) until one cycle of 28 days is complete
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- GLIX1-C101
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .